RevvityRVTY
RVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,000
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $1.77M | Put options by funds: $1.48M
19% more repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 161
15% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 60
3.87% more ownership
Funds ownership: 87.62% [Q3] → 91.49% (+3.87%) [Q4]
0% more funds holding
Funds holding: 517 [Q3] → 518 (+1) [Q4]
4% less capital invested
Capital invested by funds: $13.8B [Q3] → $13.2B (-$544M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$102
14%
upside
Avg. target
$126
40%
upside
High target
$145
62%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Baird Catherine Ramsey 24% 1-year accuracy 4 / 17 met price target | 41%upside $127 | Outperform Maintained | 21 Apr 2025 |
Wells Fargo Brandon Couillard 24% 1-year accuracy 6 / 25 met price target | 14%upside $102 | Equal-Weight Maintained | 17 Apr 2025 |
Barclays Luke Sergott 28% 1-year accuracy 16 / 57 met price target | 23%upside $110 | Overweight Maintained | 10 Apr 2025 |
Raymond James Andrew Cooper 0% 1-year accuracy 0 / 16 met price target | 62%upside $145 | Outperform Reiterated | 3 Feb 2025 |
Keybanc Paul Knight 11% 1-year accuracy 1 / 9 met price target | 62%upside $145 | Overweight Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 6 articles about RVTY published over the past 30 days
Negative
Zacks Investment Research
21 hours ago
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
2 weeks ago
Revvity to Hold Earnings Call on Monday, April 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of t.
Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's strong product portfolio raises optimism about the stock.
Neutral
Business Wire
2 weeks ago
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster hig.
Neutral
Business Wire
2 weeks ago
Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle. The Signals One platform addresses the growing complexity of drug modalities research by delivering a complete solution that integrates advanced research capabilities a.
Negative
Investors Business Daily
3 weeks ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
Positive
Zacks Investment Research
1 month ago
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
Neutral
Business Wire
1 month ago
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.
Neutral
Business Wire
1 month ago
Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN's Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN's serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to ser.
Neutral
Business Wire
1 month ago
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operat.
Charts implemented using Lightweight Charts™